遠大醫藥(00512.HK)斥資2,500萬歐元入股德國ITM 1.31%
遠大醫藥(00512.HK)公佈,與德國ITM訂立股權投資協議,集團將以2,500萬歐元認購 ITM新股,相當於其擴大後股本約1.31%。
ITM 2004年在德國慕尼黑成立,專注於研發、生產和全球供應醫用放射性同位素以及用於各種靶向診療腫瘤的放射性藥物的生物技術。此前,集團已獲得ITM開發用於診斷胃腸胰腺神經內分泌瘤的TOCscan及ITM-11,以及用於治療惡性腫瘤骨轉移的ITM-41在內的3款全球創新型放射性核素偶聯藥物在大中華區獨家開發、生產及商業化權益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.